Obesity related to the use of psychotropic drugs, considered in its psychodynamic aspect
Related Experiment Video
Updated: Aug 8, 2026

Self-Administration of Drugs in Mouse Models of Feeding and Obesity
Published on: June 8, 2021
Abstract:
It is a well known fact that one of the side-effects of the psychotropic drugs is a disturbance of body weight in the form of obesity. We believe this to be a serious side-effect because obesity is often the main reason why the patient discontinues his psychopharmaaceutical therapy, thereby causing a recrudescence of his mental illness. We have proposed that this type of obesity be designated by the diagnostic term "psychopharmacotherapeutic obesity". This paper contains a formulation and discussion of views and concepts related to a consideration of the psychodynamic aspect of the subject. Special emphasis has been given to commenting on the problem of psychopharmacotherapeutic obesity from the standpoint of etiogenesis, psychological effects, and its importance in relation and conjunction with the development and formation of the individuals' psychosomatic identity.
Related Concept Videos
Psychosis: Goals of Pharmacotherapy
Antidepressant Drugs: MAOIs and Other Agents
Obesity
Drug Dosing: Obese Patients
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

